Cargando…

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab

In light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC). Several additional trials are ongoing that combine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Chiun, Rimassa, Lorenza, Sun, Hui-Chuan, Vogel, Arndt, Kaseb, Ahmed O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Immunotherapy in Hepatocellular Carcinoma: A New Kid on the Block
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327224/ https://www.ncbi.nlm.nih.gov/pubmed/34377156 http://dx.doi.org/10.1177/17588359211031141

Ejemplares similares

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
por: Liu, Ze-Long, et al.
Publicado: (2021)

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation
por: Wan, Ping, et al.
Publicado: (2014)

Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Thema: Ziekepietjes
por: Overduin, Carla
Publicado: (2022)

Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma
por: Huang, Fei, et al.
Publicado: (2022)

Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Liu, Shanshan, et al.
Publicado: (2023)

Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
por: Zhao, Dongxu, et al.
Publicado: (2023)

Baseline characteristics associated with survival in patients with hepatocellular carcinoma
por: Aslanov, Seymur, et al.
Publicado: (2021)

Artificial intelligence method to predict overall survival of hepatocellular carcinoma
por: Simsek, Cem, et al.
Publicado: (2021)

Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
Publicado: (2021)

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
por: Mao, Lili, et al.
Publicado: (2022)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2022)

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
por: West, Howard Jack, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Efficacy of profound versus moderate neuromuscular blockade in enhancing postoperative recovery after laparoscopic donor nephrectomy: A randomised controlled trial
por: Bruintjes, Moira H.D., et al.
Publicado: (2019)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment
por: Da Rosa, M.R., et al.
Publicado: (2011)

The Significance of the Presence of Lactic Acid, and of Deficiency or Absence of Free Hydrochloric Acid, in the Gastric Contents as a Means of Diagnosis
Publicado: (1907)

Bronchoscopic Diagnosis of Carcinoma of the Lung
por: Scarff, Gordon
Publicado: (1936)

Primary Carcinoma of the Lung Radiologically Considered
por: Bush, Gilbert B.
Publicado: (1936)

The Treatment of Carcinoma of the Lung
por: Wood, Duncan
Publicado: (1936)

The Pathological Aspect
por: Taylor, Arthur L.
Publicado: (1936)

Clinical Features
por: Perry, C. Bruce
Publicado: (1936)

Nasopharyngeal carcinoma – Improving cure with technology and clinical trials
por: Tsang, Raymond K.
Publicado: (2020)

Real time in-vivo miniature endoscopic surveillance system for imaging of nasopharynx
por: Lim, Chwee Ming, et al.
Publicado: (2020)

Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxane-based induction chemotherapy and concurrent chemo-radiotherapy in the modern era
por: Ghosh-Laskar, Sarbani, et al.
Publicado: (2020)

Dysphagia after chemo-radiation for nasopharyngeal cancer: A scoping review
por: Fong, Raymond, et al.
Publicado: (2020)

Repeated exposure to fractional CO(2) laser delays squamous cell carcinoma formation and prevents clinical and subclinical photodamage visualized by line‐field confocal optical coherence tomography and histology
por: Olesen, Uffe H., et al.
Publicado: (2022)

Laser therapy as a treatment for chronic radiation fibrosis
por: Wilson, Britney, et al.
Publicado: (2022)

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma
por: Manzar, Gohar Shahwar, et al.
Publicado: (2022)

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
por: Awiwi, Muhammad O, et al.
Publicado: (2022)

Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
por: Bianco, Andrea, et al.
Publicado: (2019)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5cupbv10ihbaiq95k569io61u3